What Has Changed in Our Thinking Since ESC Munich?
In this review, individual study names, acronyms, and detailed statistical data have deliberately been omitted. When multiple study names, abbreviations, and numbers appear one after another, readers often lose sight of the main message and shift their attention toward remembering specific studies.
A different approach has been taken here. Every fact and conclusion presented can be verified through the official materials of ESC Congress 2026 Munich, the presentations, and the relevant scientific publications. The aim of this article is not to create a catalogue of studies. It is to understand what overall direction emerged in Munich, what new ideas connect the presented data and, most importantly, how our clinical thinking about atrial fibrillation is changing as a result.
Atrial fibrillation has long ceased to be simply an “irregular rhythm” whose management can be reduced to a few questions — rate or rhythm, anticoagulation or not, ablation or medication. After ESC Congress 2026 in Munich, this has become even clearer. The management of atrial fibrillation is rapidly moving from applying a single algorithm to a single diagnosis toward individualized, phenotype-based medicine.
Today, the key question is no longer simply: “Does the patient have AF?” More importantly, we need to know what type of AF they have, how high their arrhythmic burden is, what the structure and function of the left atrium are, what substrate underlies the arrhythmia, how high their actual risk of stroke and bleeding is, what comorbidities they have and, ultimately, what a particular intervention will mean for that individual.
This shift is also reflected in new data on stroke prevention. Until now, the decision to use anticoagulation has largely been based on risk scores. It is now becoming apparent that even in some patients with relatively low or intermediate risk, anticoagulation may provide meaningful stroke prevention. At the same time, we have learned the opposite lesson: in patients who have previously experienced an intracranial hemorrhage, intensifying anticoagulation may come at the cost of increased bleeding without providing an overall clinical benefit.
Therefore, calculating the score remains essential, but the score no longer replaces clinical judgment. The question should not simply be, “What is the patient’s CHA₂DS₂-VA score?” but rather: in this particular patient, does the expected benefit of stroke prevention outweigh the actual risk of bleeding?
The same philosophy has emerged in antithrombotic treatment. Adding more medications in a high-risk patient does not automatically mean better protection. Particularly when AF coexists with acute coronary disease, overly intensive antithrombotic treatment may primarily increase bleeding without providing additional cardiovascular benefit. In other words, modern management is gradually moving away from the principle that “more treatment is better” and toward a more complex but more appropriate formula: the right treatment — for the right patient — at the right intensity.
An equally important shift has occurred in rhythm control. Catheter ablation is one of the most important contemporary treatments for AF, but an important question was raised in Munich: what does successful ablation actually mean? If AF is significantly reduced after the procedure, but the patient’s quality of life does not improve to the same extent, can we say that the treatment has been completely successful based solely on the ECG? As it turns out, objective reduction in arrhythmia and subjective well-being do not always improve in parallel.
This does not diminish the importance of ablation. On the contrary, it forces us to assess outcomes more broadly. What matters is not only sinus rhythm, but also AF burden, symptoms, hospitalization, physical function, and quality of life. In the future, therefore, the statement “the ablation was successful” will increasingly mean more than a single ECG result.
At the same time, the approach to ablation itself is changing. Particularly in long-standing AF, it is becoming increasingly clear that not all atria are the same. One patient may have relatively preserved atrial tissue, while another may have extensive electrical and structural remodeling, fibrosis, and low-voltage areas. Consequently, the same anatomical procedure cannot be optimal for every patient. Data presented in Munich further strengthened the idea that, in appropriately selected patients with long-standing AF, treating individually identified abnormal substrate in addition to PVI may provide better outcomes. This represents an important shift: from standard PVI toward substrate- and phenotype-based ablation.
Another important issue then emerges — age. We still often hear the question: “Is ablation worthwhile in a 75- or 80-year-old patient?” Modern thinking increasingly relies less on the age written in a patient’s passport. What matters much more is the condition of the atrial substrate, the duration and arrhythmic burden of AF, the size and function of the left atrium, concomitant heart failure, kidney function, overall frailty, and the patient’s biological condition as a whole. In other words, the question is gradually changing from “How old is the patient?” to “How advanced is their atrial disease, and how modifiable is that substrate?”
For the same reason, the concept of AF burden is becoming increasingly important. For years, we viewed AF almost as a binary condition — it was either present or absent. Yet two patients with the same diagnosis may be living in completely different realities. One may have several short episodes a year, while another may spend a significant amount of time in fibrillation. Therefore, “the patient has AF” is becoming increasingly insufficient information. What matters is how much AF the patient has, how long the episodes last, whether their frequency is increasing, whether the disease is progressing, and what substrate it is developing on.
Wearable devices, prolonged ECG monitoring, and implantable devices have significantly expanded our ability to answer these questions. AI is now being added to this field as well — for early AF detection, risk prediction, substrate characterization, and better identification of ablation targets. However, another important message from Munich was that technology itself is not treatment. A mobile application, smartwatch, remote monitoring system, or AI are only tools. They improve outcomes only when properly integrated into clinical decision-making and when the patient actively participates in the process. Therefore, as digital cardiology develops, the physician’s role becomes even more important — not simply as a recipient of data, but as the person who must determine which of many different data points actually matter for that particular patient.
Perhaps the most interesting change, however, did not take place in the catheterization laboratory at all. Munich once again demonstrated that lifestyle modification is a genuine part of AF treatment. Structured and individualized physical activity improved not only physical condition but also reduced AF burden and hospitalizations. Therefore, telling a patient, “Lose weight, exercise, control your blood pressure, reduce alcohol intake, and treat sleep apnea,” should no longer be a general recommendation added at the end of a consultation — it is active therapy for AF.
This is where the Munich 2026 findings align with the already familiar AF-CARE concept — management of comorbidities and risk factors, stroke prevention, individualized rate and rhythm control, and continuous reassessment. But in 2026, one new word is becoming increasingly prominent within this framework: personalization. Who needs anticoagulation earlier? For whom is the bleeding risk too high? Who can be adequately treated with PVI alone? Who needs additional substrate treatment? For whom is the main goal of ablation to reduce AF burden, for whom is it symptom improvement, and for whom is it preventing disease progression? And how accurately can we predict all of this in advance?
Therefore, if we had to summarize in one sentence what happened to our thinking about atrial fibrillation in Munich, it might be this: we are gradually moving away from the approach of “one AF — one algorithm” and toward an era of personalized medicine for atrial fibrillation. Managing AF no longer means simply restoring sinus rhythm. It means preventing stroke, reducing arrhythmic burden, slowing the progression of atrial disease, actively managing comorbidities, avoiding unnecessary treatment and, ultimately, achieving not just a better ECG, but a better outcome for the patient.
Perhaps the main question emerging from Munich 2026 is no longer, “How should we treat atrial fibrillation?” but rather, “How should we treat the individual person who has atrial fibrillation?” And it is from this question that a new era in AF management begins.
— David Malidze, cardiologist, writes on social media.
